Posted by Michael Wonder on 26 Sep 2024
Health Canada grants marketing authorisation of first CRISPR/Cas9 gene edited therapy, Casgevy (exagamglogene autotemcel), for the treatment of sickle cell disease and transfusion-dependent beta thalassaemia
25 September 2024 - First regulatory authorisation of a CRISPR-based gene-editing therapy in Canada.
Vertex Pharmaceuticals today announced Health Canada has granted marketing authorisation for Casgevy (exagamglogene autotemcel), an autologous genome edited haematopoietic stem cell-based therapy, for the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassaemia.
